Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements. Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
用于需要鞘内治疗且对其他镇痛治疗(如应用全身性镇痛药或鞘内注射吗啡等)不耐受或疗效差的严重慢性疼痛患者。
The Ohio State University Department of Neurology, Columbus, Ohio, United States
Clearwater Pain Management, Clearwater, Florida, United States
Integrated Pain Solutions, Columbus, Ohio, United States
Desert Pain Institute, Mesa, Arizona, United States
Pain and Rehabilitation Centre, University Hospital, Linköping, Sweden
Istituto Nazionale dei Tumori , Unita Terapia Antalgica, Napoli, Italy
The University of Chicago, Dept. of Surgery, Section of Neurosurgery, Chicago, Illinois, United States
The Center for Pain Relief, Charleston, West Virginia, United States
Alabama Pain Center, Huntsville, Alabama, United States
Emory Univ Hosp, Atlanta, Georgia, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.